Johnston, Patrick B.
Cashen, Amanda F.
Nikolinakos, Petros G.
Beaven, Anne W.
Barta, Stefan Klaus
Bhat, Gajanan
Hasal, Steven J.
De Vos, Sven
Oki, Yasuhiro
Deng, Changchun
Foss, Francine M.
Funding for this research was provided by:
Spectrum Pharmaceuticals
Acrotech Biopharma
Onxeo S.A
Article History
Received: 5 October 2020
Accepted: 22 January 2021
First Online: 18 February 2021
Ethics approval and consent to participate
: The study protocol and patient materials were approved by institutional review boards and/or ethics committees at all sites. Study conduct followed International Conference on Harmonization (ICH) Guidelines for Good Clinical Practice, including written informed consent and monitoring of all data.
: N/A.
: A.C has received funding from Celgene, and is part of the Speaker's Bureau for Seattle Genetics and Novartis. S.B. has received research funding from Seattle Genetics. G.B, G.R, S.H are employees of Spectrum Pharmaceuticals. F.F. has been a consultant, Speakers Bureau and received research funding from Spectrum Pharmaceuticals, Celgene, Seattle Genetics, Infinity, Millennium. The remaining authors declare that they have no conflict of interest.